These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 37311172)

  • 1. Peptide-Hypervalent Iodine Reagent Chimeras: Enabling Peptide Functionalization and Macrocyclization.
    Liu XY; Ji X; Heinis C; Waser J
    Angew Chem Int Ed Engl; 2023 Aug; 62(33):e202306036. PubMed ID: 37311172
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cys-Cys and Cys-Lys Stapling of Unprotected Peptides Enabled by Hypervalent Iodine Reagents.
    Ceballos J; Grinhagena E; Sangouard G; Heinis C; Waser J
    Angew Chem Int Ed Engl; 2021 Apr; 60(16):9022-9031. PubMed ID: 33450121
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypervalent Iodine Amino Acid Building Blocks for Bioorthogonal Peptide Macrocyclization.
    Liu XY; Mykhailenko O; Faraone A; Waser J
    Angew Chem Int Ed Engl; 2024 May; ():e202404747. PubMed ID: 38807563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypervalent Iodine-Mediated Late-Stage Peptide and Protein Functionalization.
    Allouche EMD; Grinhagena E; Waser J
    Angew Chem Int Ed Engl; 2022 Feb; 61(7):e202112287. PubMed ID: 34674359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclic Hypervalent Iodine Reagents: Enabling Tools for Bond Disconnection via Reactivity Umpolung.
    Hari DP; Caramenti P; Waser J
    Acc Chem Res; 2018 Dec; 51(12):3212-3225. PubMed ID: 30485071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Perfluoroarene-based peptide macrocycles that inhibit the Nrf2/Keap1 interaction.
    Steel RJ; O'Connell MA; Searcey M
    Bioorg Med Chem Lett; 2018 Sep; 28(16):2728-2731. PubMed ID: 29534931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rational cyclization-based minimization of entropy penalty upon the binding of Nrf2-derived linear peptides to Keap1: A new strategy to improve therapeutic peptide activity against sepsis.
    Chen K; Huang L; Shen B
    Biophys Chem; 2019 Jan; 244():22-28. PubMed ID: 30465941
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cysteine-Cysteine Cross-Conjugation of both Peptides and Proteins with a Bifunctional Hypervalent Iodine-Electrophilic Reagent.
    Koutsopetras I; Mishra AK; Benazza R; Hernandez-Alba O; Cianférani S; Chaubet G; Nicolai S; Waser J
    Chemistry; 2023 Dec; 29(70):e202302689. PubMed ID: 37712523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amphiphilic Iodine(III) Reagents for the Lipophilization of Peptides in Water.
    Mishra AK; Tessier R; Hari DP; Waser J
    Angew Chem Int Ed Engl; 2021 Aug; 60(33):17963-17968. PubMed ID: 34038604
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recyclable hypervalent iodine(III) reagent iodosodilactone as an efficient coupling reagent for direct esterification, amidation, and peptide coupling.
    Tian J; Gao WC; Zhou DM; Zhang C
    Org Lett; 2012 Jun; 14(12):3020-3. PubMed ID: 22671301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recapitulating the Binding Affinity of Nrf2 for KEAP1 in a Cyclic Heptapeptide, Guided by NMR, X-ray Crystallography, and Machine Learning.
    Ortet PC; Muellers SN; Viarengo-Baker LA; Streu K; Szymczyna BR; Beeler AB; Allen KN; Whitty A
    J Am Chem Soc; 2021 Mar; 143(10):3779-3793. PubMed ID: 33683866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A systematic molecular dynamics approach to the study of peptide Keap1-Nrf2 protein-protein interaction inhibitors and its application to p62 peptides.
    Lu MC; Yuan ZW; Jiang YL; Chen ZY; You QD; Jiang ZY
    Mol Biosyst; 2016 Apr; 12(4):1378-87. PubMed ID: 26935067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of a Cell-Permeable Cyclic Peptidyl Inhibitor against the Keap1-Nrf2 Interaction.
    Salim H; Song J; Sahni A; Pei D
    J Org Chem; 2020 Feb; 85(3):1416-1424. PubMed ID: 31609620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Palladium-Catalyzed Organic Reactions Involving Hypervalent Iodine Reagents.
    Shetgaonkar SE; Mamgain R; Kikushima K; Dohi T; Singh FV
    Molecules; 2022 Jun; 27(12):. PubMed ID: 35745020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of a head-to-tail cyclic peptide as the Keap1-Nrf2 protein-protein interaction inhibitor with high cell potency.
    Lu MC; Jiao Q; Liu T; Tan SJ; Zhou HS; You QD; Jiang ZY
    Eur J Med Chem; 2018 Jan; 143():1578-1589. PubMed ID: 29117896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recyclable hypervalent-iodine-mediated solid-phase peptide synthesis and cyclic peptide synthesis.
    Liu D; Guo YL; Qu J; Zhang C
    Beilstein J Org Chem; 2018; 14():1112-1119. PubMed ID: 29977383
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis of water-soluble hypervalent iodine reagents for fluoroalkylation of biological thiols.
    Klimánková I; Hubálek M; Matoušek V; Beier P
    Org Biomol Chem; 2019 Dec; 17(47):10097-10102. PubMed ID: 31754683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Direct Photoexcitation of Ethynylbenziodoxolones: An Alternative to Photocatalysis for Alkynylation Reactions*.
    Amos SGE; Cavalli D; Le Vaillant F; Waser J
    Angew Chem Int Ed Engl; 2021 Oct; 60(44):23827-23834. PubMed ID: 34403571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tyrosine bioconjugation with hypervalent iodine.
    Declas N; Maynard JRJ; Menin L; Gasilova N; Götze S; Sprague JL; Stallforth P; Matile S; Waser J
    Chem Sci; 2022 Nov; 13(43):12808-12817. PubMed ID: 36519034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent progress in Keap1-Nrf2 protein-protein interaction inhibitors.
    Mou Y; Wen S; Li YX; Gao XX; Zhang X; Jiang ZY
    Eur J Med Chem; 2020 Sep; 202():112532. PubMed ID: 32668381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.